Eculizumab
Resources to support the choice of eculizumab biosimilar within organisations.
Preparing to use eculizumab biosimilar
Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing eculizumab biosimilar
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for eculizumab biosimilars
Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Natalizumab
Resources to support the choice of natalizumab biosimilar within organisations.
Preparing to use natalizumab biosimilar
Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Good governance when implementing natalizumab biosimilar
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
Ranibizumab for ocular use
Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.
Preparing to use ranibizumab biosimilar
Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
Good governance when implementing ranibizumab biosimilar
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
The licence and supporting evidence for ranibizumab biosimilars
Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Tocilizumab
Resources to support the choice of tocilizumab biosimilar within organisations.
Preparing to use tocilizumab biosimilar
Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing tocilizumab biosimilar
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for tocilizumab biosimilar
One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
Ustekinumab
Preparing to use ustekinumab biosimilar
Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.